Lymphoma is a medical term for blood cancer. Development of lymphoma indicates abnormal growth of B or T lymphocytes and also if these cells survive longer than their normal cycle. Lymphoma is generally found in bone marrow, spleen, and other parts that constitute the lymphatic system.
On the basis of type, Lymphoma is divided into two types viz, Hodgkin and non-hodgkin. In Hodgkin’s disease the blood cancer starts in the lymphatic system and is also called as hodgkin’s lymphoma or Hodgkinlymphoma. Common symptoms include swelling of lymph nodes which causes a lump to develop under the skin. Diagnostic measures include imaging tests such as X-rays or CT scans, lymph node biopsy, blood tests, bone marrow biopsy, lung function tests and other. However, the associated side-effects of Hodgkin lymphoma include radiation which includes lung cancer, heart disease and breast cancer.
In non-hodgkin lymphoma, the cells called as lymphocytes are affected which function as the immune in the body. Simply, in non-hodgkin’s lymphoma, immune cells grow abnormally. Common symptoms include enlarged lymph nodes, chest pain or pressure, fever, weight loss,fatigue and others. Diagnosis includes biopsy, blood tests, bone marrow samples, chest x-ray, CT-scan and others. However, the associate side-effects are feeling of being sick, diarrhea, hair loss or thinning and feeling of weakness.
Despite of the side-effects, chemotherapy is the suggested diagnostic measure for Lymphoma.
The major driving factors of this market are growing prevalence of lymphoma across the globe. In the entire U.S and Canada around 6 million people suffered from lymphoma. The government has started extensive R&D in this regards and emphasizes on advanced drugs development to boost the lymphoma market.
The lymphoma market faces some restraints like side effects of chemotherapy which includes hair loss, vomiting and fatigueand nausea. Additionally, high costs for treatment may also hinder the growth of this market.
The drugs used in the treatment of lymphoma includes Adcertis (brentuximab), Adriamycin (doxorubicin), Decadron (dexamethasone), Baycadron (dexamethasone), Deltasone (prednisone), Dexpak Taperpak (dexamethsone), Folotyn (pralatrexate), Dexamethasone intenol (dexamethasone), Solurex (dexamethasone), Leukeran (chlorambucil), Zemapak (dexamethasone), Velcade (bortezomib), Thioplex (thiotepa), Velban (vinblastine), Sterapred DS (prednisone) and Trexall (methotrexate)
On the basis of geography, the global market is segmented into North America, Europe, Asia-Pacific, Middle-east and Africa. North America dominates the global market owing to factors like establishment of developing and manufacturing lymphoma treating drugs and government funding. Asia-pacific is predicted to be the emerging market for forecast period and is expected to grow at a higher CAGR owing to growing prevalence of lymphoma in the APAC regions. Additionally, increasing awareness about health would further propel the growth of lymphoma market in the APAC regions.
The key players in the market include Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, ABIOGEN PHARMA S.p.A., Johnson & Johnson, AeternaZentaris, Inc. and Merck & Co., Inc.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.